Rigontec GmbH, is a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.
Rigontec focus on the development of synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), which recognizes viral RNA. RNA motifs that activate RIG-I promote the destruction of diseased cells and the induction of a lasting immune memory thereby treating and preventing recurrence of disease.
Rigontec’s, a proprietary first-in-class product targeting RIG-I, is currently being evaluated for development in several cancer types including melanoma and prostate cancer. ImOl100 is a chemically synthesized mimic of the natural ligand of RIG-I with improved safety and drug like properties. In various preclinical models, ImOl100 has demonstrated substantial tumor regression and systemic anti-tumor activity including long-term protection against tumor rechallenge. Rigontec’s technology also allows the design of pipeline candidates with additional gene silencing and inhibitory activities. Rigontec is financed by top-tier VC investors and is seeking to realize the full potential of its technology by developing an internal pipeline into the clinic.
Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics
Rigontec GmbH raises €4.8m in a second closing of its Series A financing
Rigontec GmbH raises € 9.45 m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases
Info & Contact